Investigating the Role of RPL8 Protein in Ovarian Cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to explore the role of the RPL8 protein in high-grade serous ovarian carcinoma (HGSOC) by analyzing tumor tissue samples. Researchers will assess the frequency of RPL8 gene amplification and its correlation with clinical outcomes and treatment responses. The study seeks to determine if RPL8 can serve as a biomarker for risk assessment and patient stratification in therapeutic decision-making. The findings could provide new insights into the biology of HGSOC, which is often poorly understood.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 18 years.
* Diagnosis of high-grade (3 or 4) serous ovarian carcinoma, either at onset or recurrence.
* Signed informed consent to participate in the study.

Exclusion Criteria:

* Ovarian tumors of histological types other than serous.
* Other primary tumor types.

Where it's running

• IRCCS Azianda Ospedaliero-Universitaria di Bologna
  Bologna, Bo, Italy Recruiting

Study contacts

• Principal investigator: Lorenzo Montanaro, MD — IRCCS Azienda Ospedaliero-Universitaria di Bologna
• Study coordinator: Lorenzo Montanaro, MD
• Email: lorenzo.montanaro@aosp.bo.it
• Phone: +390512144524

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• FRα expression in high-grade serous ovarian cancer (FRα positive)

  A retrospective study in Greece will test how often Folate Receptor Alpha is present in tumor samples from adults diagnosed with high-grade serous ovarian cancer.

  Recruiting Hellenic Cooperative Oncology Group · Athens · NCT07889843

• Routine shallow-coverage Whole Genome Sequencing of Cervical Smears to See if Ovarian Cancer is Found Earlier

  Researchers test whether analyzing DNA from cervical smears with shallow whole-genome sequencing can help detect high-grade serous ovarian cancer early in patients undergoing treatment for this cancer.

  Recruiting Institut Claudius Regaud · Toulouse · NCT07821879

• IDE034 for adults with advanced solid tumors that express B7-H3 and PTK7

  This trial will test IDE034 to see if it is safe and works in adults with advanced or metastatic solid tumors that express B7-H3 and PTK7.

  Recruiting at 26 sites Phase 1 IDEAYA Biosciences · Duarte, California and 25 other locations · NCT07503808

• Idetrexed plus olaparib for high-grade serous ovarian cancer

  This trial tests whether combining idetrexed and olaparib helps people with high-grade serous ovarian cancer that is resistant to standard treatments.

  Recruiting Phase 1 Institute of Cancer Research, United Kingdom · Cambridge, Cambridgeshire and 2 other locations · NCT06976892

• Exploring Tumor Biology in Ovarian Cancer with Advanced Imaging Techniques

  This study is testing new imaging techniques to better understand ovarian cancer tumors and improve personalized treatment for patients.

  Recruiting Institut du Cancer de Montpellier - Val d'Aurelle · Montpellier · NCT06084195

• Testing Rinatabart Sesutecan for advanced solid tumors

  This study is testing a new drug called Rinatabart Sesutecan to see if it can safely help people with advanced solid tumors, like certain types of ovarian and endometrial cancers.

  Recruiting at 67 sites Phase 1/2 Genmab · Phoenix, Arizona and 66 other locations · NCT05579366

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.